Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof

A monoclonal antibody which specifically binds to CLDN18.2, comprising:

• (1) a heavy chain complementarity determining region 1 (HCDR1) as set forth in SEQ ID NO:
• 17, a HCDR2 as set forth in SEQ ID NO:
• 18, a HCDR3 as set forth in SEQ ID NO:
• 19, a light chain complementarity determining region 1 (LCDR1) as set forth in SEQ ID NO:
• 20, a LCDR2 as set forth in SEQ ID NO:
• 21, and a LCDR3 as set forth in SEQ ID NO:
• 22;
• (2) a HCDR1 as set forth in SEQ ID NO:
• 41, a HCDR2 as set forth in SEQ ID NO:
• 42, a HCDR3 as set forth in SEQ ID NO:
• 43, a LCDR1 as set forth in SEQ ID NO:
• 44, a LCDR2 as set forth in SEQ ID NO:
• 45, and a LCDR3 as set forth in SEQ ID NO:
• 46;
• (3) a HCDR1 as set forth in SEQ ID NO:
• 47, a HCDR2 as set forth in SEQ ID NO:
• 48, a HCDR3 as set forth in SEQ ID NO:
• 49, a LCDR1 as set forth in SEQ ID NO:
• 50, a LCDR2 as set forth in SEQ ID NO:
• 51, and a LCDR3 as set forth in SEQ ID NO:
• 52;
• or
• (4) a HCDR1 as set forth in SEQ ID NO:
• 53, a HCDR2 as set forth in SEQ ID NO:
• 54, a HCDR3 as set forth in SEQ ID NO:
• 55, a LCDR1 as set forth in SEQ ID NO:
• 56, a LCDR2 as set forth in SEQ ID NO:
• 57, and a LCDR3 as set forth in SEQ ID NO:
• 58.